The effects of chronic prostacyclin therapy on cardiac output and symptoms in primary pulmonary hypertension
- 1 October 1999
- journal article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 34 (4), 1184-1187
- https://doi.org/10.1016/s0735-1097(99)00320-4
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Angiotensin II mediates systemic rebound hypertension after cessation of prostacyclin infusion in sheepJournal of Applied Physiology, 1998
- Reduction in Pulmonary Vascular Resistance with Long-Term Epoprostenol (Prostacyclin) Therapy in Primary Pulmonary HypertensionNew England Journal of Medicine, 1998
- Primary Pulmonary Hypertension: Improved Long-Term Effects and Survival With Continuous Intravenous Epoprostenol InfusionJournal of the American College of Cardiology, 1997
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- New insights into mechanisms underlying nitrate toleranceThe American Journal of Cardiology, 1996
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Neurohormonal activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levelsJournal of the American College of Cardiology, 1995
- Primary Pulmonary HypertensionAnnals of Internal Medicine, 1987
- Positive inotropic effect of a stable analogue of PGI2 and of PGI2 on isolated guinea pig atria. Mechanism of actionPharmacological Research Communications, 1983
- Prostacyclin is a circulating hormoneNature, 1978